- Active Ingredients
Product Documentation
-
View RMM (RMM- Apixaban Patient Alert Card)
Last updated on this site: 04 Sep 2025
Description of update: To update the Patient Alert Card in line with the reference product (Eliquis 2.5 mg/ 5 mg film-coated tablets; PLGB number: PLGB 54213/0001-0002; MAH: Bristol-Myers Squibb/Pfizer EEIG, Ireland).
Date of approval: 22/08/2025
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at yellowcard.mhra.gov.uk. By reporting side effects, you can help provide more information on the safety of this medicine.
Report a side effect or a product complaintApixaban Accord 2.5mg film-coated tablets
- PL Number:
- PLGB 20075/1405
- MA Holder:
- Accord Healthcare Limited
- Product Classification:
-
POM
- Product Status:
- Active
Product Documentation
-
View Summary of Product Characteristics (SmPC- Apixaban Accord 2.5 mg Film-coated tablets)
Last updated on this site: 01 Sep 2025
Description of update: To update section 4.8 of the SmPC in line with the reference product (Eliquis 2.5 mg/ 5 mg film-coated tablets; PLGB number: PLGB 54213/0001-0002; MAH: Bristol-Myers Squibb/Pfizer EEIG, Ireland). Consequently, the leaflet and Patient Alert Card is being updated. Additionally, editorial changes have been made to sections 4.2, 4.4, 4.6 of SmPC for 5 mg strength and sections 2, 3 of the leaflet.
Date of approval: 22/08/2025
SmPC sections updated: 4.8, 9 and 10
View Patient Information Leaflet (PIL-Apixaban Accord 2.5 mg film-coated tablets)Last updated on this site: 01 Sep 2025
Description of update: To update section 4.8 of the SmPC in line with the reference product (Eliquis 2.5 mg/ 5 mg film-coated tablets; PLGB number: PLGB 54213/0001-0002; MAH: Bristol-Myers Squibb/Pfizer EEIG, Ireland). Consequently, the leaflet and Patient Alert Card is being updated. Additionally, editorial changes have been made to sections 4.2, 4.4, 4.6 of SmPC for 5 mg strength and sections 2, 3 of the leaflet.
Date of approval: 22/08/2025
PIL sections updated: 2, 3, 4 and 6
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at yellowcard.mhra.gov.uk. By reporting side effects, you can help provide more information on the safety of this medicine.
Report a side effect or a product complaint
For any further assistance, please get in touch.